{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: GI-001\nAge: 58\nCancer Type: Melanoma\n\nMEDICATIONS:\nPembrolizumab 200mg IV q3weeks, Ondansetron 8mg PRN, Lisinopril 10mg daily\n\nLABORATORY VALUES:\nWBC: 11.2 x10^9/L (H), CRP: 2.8 mg/dL (H), Albumin: 3.2 g/dL (L), Hemoglobin: 12.5 g/dL\n\nSYMPTOMS:\nDiarrhea - 5-6 loose stools daily for 4 days, Abdominal cramping - mild, No blood in stool, No fever\n\nCLINICAL NOTES:\nPatient on cycle 4 of pembrolizumab for stage IIIC melanoma. Reports onset of loose stools 4 days ago, now having 5-6 episodes daily. Mild periumbilical cramping. No mucus or blood. Appetite slightly decreased. No recent antibiotic use. No sick contacts.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on pembrolizumab (PD-1 inhibitor) cycle 4\",\"step2_organ_findings\":\"GI system: 5-6 loose stools/day x 4 days with mild cramping. No blood, no fever.\",\"step3_severity_rationale\":\"CTCAE Grade 2 diarrhea: 4-6 stools/day over baseline. Patient has 5-6 stools = Grade 2.\",\"step4_causality_rationale\":\"On ICI with typical presentation, no alternative cause identified\",\"step5_urgency_rationale\":\"Grade 2 = minimum 'soon' urgency per protocol\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"pembrolizumab\"],\"drug_classes\":[\"PD-1\"],\"combination_therapy\":false,\"context_notes\":\"Cycle 4 of pembrolizumab\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Gastrointestinal\",\"detected\":true,\"findings\":[\"5-6 loose stools daily\",\"Mild abdominal cramping\"],\"evidence\":[\"Elevated WBC\",\"Elevated CRP\",\"Low albumin\"],\"severity\":\"Grade 2\"}],\"causality\":{\"likelihood\":\"Possible\",\"reasoning\":\"Patient on PD-1 inhibitor with classic Grade 2 diarrhea pattern during active treatment\",\"temporal_relationship\":\"Onset during cycle 4\",\"alternative_causes\":[],\"supporting_factors\":[\"On checkpoint inhibitor\",\"Typical Grade 2 pattern\",\"No alternative cause\"],\"against_factors\":[\"No blood in stool\",\"No fever\"]},\"overall_severity\":\"Grade 2 - Moderate\",\"severity_reasoning\":\"CTCAE Grade 2 Diarrhea: 4-6 stools/day over baseline. Patient reports 5-6 loose stools daily.\",\"urgency\":\"soon\",\"urgency_reasoning\":\"Grade 2 GI toxicity requires oncology review within 1-3 days\",\"recommended_actions\":[{\"action\":\"Hold pembrolizumab pending evaluation\",\"priority\":1,\"rationale\":\"Grade 2 colitis typically requires treatment hold\"},{\"action\":\"Start oral prednisone 1mg/kg daily\",\"priority\":1,\"rationale\":\"Standard first-line treatment for Grade 2 colitis\"},{\"action\":\"Obtain stool studies to rule out infectious etiology\",\"priority\":2,\"rationale\":\"Must exclude C. diff and other infections\"}],\"key_evidence\":[\"5-6 loose stools daily\",\"On pembrolizumab\",\"Elevated CRP\",\"Low albumin\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: GI-002\nAge: 65\nCancer Type: Non-small cell lung cancer\n\nMEDICATIONS:\nNivolumab 480mg IV q4weeks, Prednisone 10mg daily (started 2 days ago), Loperamide 2mg PRN\n\nLABORATORY VALUES:\nWBC: 14.5 x10^9/L (H), CRP: 8.5 mg/dL (H), Albumin: 2.8 g/dL (L), Potassium: 3.2 mEq/L (L), Creatinine: 1.4 mg/dL (H)\n\nSYMPTOMS:\nDiarrhea - 8-10 watery stools daily, Blood in stool - present, Severe abdominal pain, Fever - 38.2°C, Dehydration signs\n\nCLINICAL NOTES:\nPatient on nivolumab for metastatic NSCLC. Severe watery diarrhea started 1 week ago, now with visible blood. Diffuse abdominal tenderness on exam. Signs of dehydration. Started low-dose prednisone 2 days ago without improvement.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on nivolumab (PD-1 inhibitor)\",\"step2_organ_findings\":\"GI: 8-10 bloody stools/day, severe pain, fever, dehydration\",\"step3_severity_rationale\":\"CTCAE Grade 3: ≥7 stools/day OR bloody diarrhea. Has both.\",\"step4_causality_rationale\":\"Classic severe colitis pattern, failed low-dose steroids\",\"step5_urgency_rationale\":\"Grade 3 = minimum 'urgent' urgency\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"nivolumab\"],\"drug_classes\":[\"PD-1\"],\"combination_therapy\":false,\"context_notes\":\"Active nivolumab therapy\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Gastrointestinal\",\"detected\":true,\"findings\":[\"8-10 watery stools daily\",\"Blood in stool\",\"Severe abdominal pain\",\"Fever\"],\"evidence\":[\"Failed low-dose steroids\",\"Dehydration\",\"Elevated CRP 8.5\"],\"severity\":\"Grade 3\"}],\"causality\":{\"likelihood\":\"Highly likely\",\"reasoning\":\"Severe bloody diarrhea on PD-1 inhibitor with fever and dehydration. Failed low-dose steroids.\",\"temporal_relationship\":\"During active immunotherapy\",\"alternative_causes\":[],\"supporting_factors\":[\"On checkpoint inhibitor\",\"Bloody diarrhea\",\"Failed low-dose steroids\",\"Fever and dehydration\"],\"against_factors\":[]},\"overall_severity\":\"Grade 3 - Severe\",\"severity_reasoning\":\"CTCAE Grade 3: ≥7 stools/day over baseline OR bloody diarrhea. Patient has 8-10 stools with blood.\",\"urgency\":\"urgent\",\"urgency_reasoning\":\"Grade 3 colitis requires same-day evaluation and hospitalization\",\"recommended_actions\":[{\"action\":\"Hospitalize for IV methylprednisolone 1-2mg/kg\",\"priority\":1,\"rationale\":\"Grade 3 colitis requires IV steroids\"},{\"action\":\"Discontinue nivolumab\",\"priority\":1,\"rationale\":\"Grade 3 toxicity requires treatment discontinuation\"},{\"action\":\"GI consultation for colonoscopy\",\"priority\":1,\"rationale\":\"Confirm diagnosis and assess severity\"},{\"action\":\"IV fluid resuscitation\",\"priority\":1,\"rationale\":\"Patient is dehydrated\"}],\"key_evidence\":[\"8-10 bloody stools daily\",\"Failed low-dose steroids\",\"Fever\",\"Dehydration\",\"Elevated CRP\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: HEP-001\nAge: 52\nCancer Type: Urothelial carcinoma\n\nMEDICATIONS:\nAtezolizumab 1200mg IV q3weeks, Metformin 1000mg BID, Omeprazole 20mg daily\n\nLABORATORY VALUES:\nAST: 156 U/L (H) - baseline 28, ALT: 189 U/L (H) - baseline 32, ALP: 145 U/L (H), Total Bilirubin: 1.8 mg/dL (H), INR: 1.1\n\nSYMPTOMS:\nFatigue - moderate, Mild nausea, No jaundice, No abdominal pain\n\nCLINICAL NOTES:\nRoutine labs show AST/ALT elevation >3x ULN. Patient asymptomatic except for mild fatigue. No alcohol use. No new medications. Viral hepatitis panel pending.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on atezolizumab (PD-L1 inhibitor)\",\"step2_organ_findings\":\"Hepatic: AST 156 (~4x ULN), ALT 189 (~4.7x ULN)\",\"step3_severity_rationale\":\"CTCAE Grade 2 hepatitis: AST/ALT >3-5x ULN\",\"step4_causality_rationale\":\"On ICI, no hepatotoxic medications, viral panel pending\",\"step5_urgency_rationale\":\"Grade 2 = minimum 'soon' urgency\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"atezolizumab\"],\"drug_classes\":[\"PD-L1\"],\"combination_therapy\":false,\"context_notes\":\"Routine labs during atezolizumab treatment\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Hepatic\",\"detected\":true,\"findings\":[\"AST 156 U/L (4x ULN)\",\"ALT 189 U/L (4.7x ULN)\",\"Mildly elevated bilirubin\"],\"evidence\":[\"Significant rise from baseline\",\"No hepatotoxic medications\"],\"severity\":\"Grade 2\"}],\"causality\":{\"likelihood\":\"Possible\",\"reasoning\":\"AST/ALT 3-5x ULN on PD-L1 inhibitor. Need to rule out viral hepatitis.\",\"temporal_relationship\":\"During active immunotherapy\",\"alternative_causes\":[\"Viral hepatitis (pending)\"],\"supporting_factors\":[\"On checkpoint inhibitor\",\"AST/ALT >3x ULN\",\"No other hepatotoxic medications\"],\"against_factors\":[\"Viral hepatitis panel pending\"]},\"overall_severity\":\"Grade 2 - Moderate\",\"severity_reasoning\":\"CTCAE Grade 2 Hepatitis: AST/ALT >3-5x ULN. AST 156 (~4x ULN) and ALT 189 (~4.7x ULN).\",\"urgency\":\"soon\",\"urgency_reasoning\":\"Grade 2 hepatitis requires oncology review to determine treatment hold\",\"recommended_actions\":[{\"action\":\"Hold atezolizumab pending evaluation\",\"priority\":1,\"rationale\":\"Grade 2 hepatitis requires treatment hold\"},{\"action\":\"Rule out viral hepatitis (HAV, HBV, HCV)\",\"priority\":1,\"rationale\":\"Must exclude infectious causes\"},{\"action\":\"Consider prednisone 0.5-1mg/kg if viral negative\",\"priority\":2,\"rationale\":\"Standard treatment for immune-related hepatitis\"},{\"action\":\"Recheck LFTs in 3-5 days\",\"priority\":2,\"rationale\":\"Monitor for progression\"}],\"key_evidence\":[\"AST 156 U/L (>3x ULN)\",\"ALT 189 U/L (>3x ULN)\",\"On atezolizumab\",\"Mildly elevated bilirubin\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: HEP-002\nAge: 48\nCancer Type: Melanoma\n\nMEDICATIONS:\nIpilimumab 3mg/kg + Nivolumab 1mg/kg IV q3weeks, Acetaminophen 500mg PRN\n\nLABORATORY VALUES:\nAST: 485 U/L (H), ALT: 612 U/L (H), ALP: 210 U/L (H), Total Bilirubin: 3.2 mg/dL (H), Direct Bilirubin: 2.1 mg/dL (H), INR: 1.4 (H), Albumin: 3.0 g/dL (L)\n\nSYMPTOMS:\nJaundice - visible scleral icterus, Fatigue - severe, Nausea and anorexia, Dark urine, Right upper quadrant discomfort\n\nCLINICAL NOTES:\nPatient on combination immunotherapy for metastatic melanoma. Developed jaundice over past week. AST/ALT >10x ULN. Hepatitis panel negative. No hepatotoxic medications. Ultrasound shows no biliary obstruction.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on combination ICI (ipilimumab + nivolumab) - HIGHEST RISK\",\"step2_organ_findings\":\"Hepatic: AST 485 (~12x ULN), ALT 612 (~15x ULN), jaundice, elevated INR\",\"step3_severity_rationale\":\"CTCAE Grade 3 hepatitis: AST/ALT >5-20x ULN with elevated bilirubin\",\"step4_causality_rationale\":\"Combination ICI with negative viral panel, no obstruction\",\"step5_urgency_rationale\":\"Grade 3 = minimum 'urgent' urgency\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"ipilimumab\",\"nivolumab\"],\"drug_classes\":[\"CTLA-4\",\"PD-1\"],\"combination_therapy\":true,\"context_notes\":\"Combination immunotherapy - highest hepatitis risk\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Hepatic\",\"detected\":true,\"findings\":[\"AST 485 U/L (12x ULN)\",\"ALT 612 U/L (15x ULN)\",\"Jaundice\",\"Elevated bilirubin\",\"Elevated INR\"],\"evidence\":[\"Negative viral panel\",\"No biliary obstruction\",\"Combination ICI\"],\"severity\":\"Grade 3\"}],\"causality\":{\"likelihood\":\"Highly likely\",\"reasoning\":\"Combination ICI (highest hepatitis risk) with severe transaminitis, jaundice, and elevated INR. Viral hepatitis ruled out.\",\"temporal_relationship\":\"During combination immunotherapy\",\"alternative_causes\":[],\"supporting_factors\":[\"Combination ICI\",\"AST/ALT >10x ULN\",\"Jaundice with elevated bilirubin\",\"Negative viral panel\",\"No biliary obstruction\"],\"against_factors\":[]},\"overall_severity\":\"Grade 3 - Severe\",\"severity_reasoning\":\"CTCAE Grade 3 Hepatitis: AST/ALT >5-20x ULN. AST 485 (~12x ULN) and ALT 612 (~15x ULN) with elevated bilirubin and INR.\",\"urgency\":\"urgent\",\"urgency_reasoning\":\"Grade 3 hepatitis requires same-day hospitalization for IV steroids\",\"recommended_actions\":[{\"action\":\"Permanently discontinue immunotherapy\",\"priority\":1,\"rationale\":\"Grade 3 hepatitis typically requires permanent discontinuation\"},{\"action\":\"Hospitalize for IV methylprednisolone 1-2mg/kg\",\"priority\":1,\"rationale\":\"Grade 3 hepatitis requires IV steroids\"},{\"action\":\"Hepatology consultation\",\"priority\":1,\"rationale\":\"Severe hepatitis needs specialist input\"},{\"action\":\"Monitor INR daily\",\"priority\":1,\"rationale\":\"Elevated INR indicates synthetic dysfunction\"}],\"key_evidence\":[\"AST 485, ALT 612 (>10x ULN)\",\"Jaundice\",\"Elevated INR 1.4\",\"Combination ICI\",\"Negative viral panel\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: LUNG-001\nAge: 67\nCancer Type: Non-small cell lung cancer\n\nMEDICATIONS:\nDurvalumab 10mg/kg IV q2weeks, Albuterol inhaler PRN, Lisinopril 20mg daily\n\nLABORATORY VALUES:\nWBC: 9.8 x10^9/L, LDH: 280 U/L (H), CRP: 3.2 mg/dL (H), Procalcitonin: 0.15 ng/mL\n\nSYMPTOMS:\nDry cough - new onset, 2 weeks, Dyspnea on exertion - moderate, No fever, O2 saturation: 94% on room air\n\nCLINICAL NOTES:\nPost-chemoradiation consolidation durvalumab. New dry cough and exertional dyspnea x 2 weeks. CT chest shows new bilateral ground-glass opacities. No infectious symptoms. Sputum culture negative.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on durvalumab (PD-L1 inhibitor) post-chemoradiation - HIGH pneumonitis risk\",\"step2_organ_findings\":\"Pulmonary: New cough, dyspnea, bilateral GGO on CT, SpO2 94%\",\"step3_severity_rationale\":\"CTCAE Grade 2 pneumonitis: Symptomatic, medical intervention indicated\",\"step4_causality_rationale\":\"Post-CRT durvalumab setting has 10-15% pneumonitis rate, negative infection workup\",\"step5_urgency_rationale\":\"Grade 2 = minimum 'soon' urgency\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"durvalumab\"],\"drug_classes\":[\"PD-L1\"],\"combination_therapy\":false,\"context_notes\":\"Post-chemoradiation consolidation - high pneumonitis risk setting\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Pulmonary\",\"detected\":true,\"findings\":[\"New dry cough\",\"Dyspnea on exertion\",\"Bilateral GGO on CT\",\"SpO2 94%\"],\"evidence\":[\"Post-CRT setting\",\"Negative infection workup\",\"Low procalcitonin\"],\"severity\":\"Grade 2\"}],\"causality\":{\"likelihood\":\"Highly likely\",\"reasoning\":\"Post-CRT durvalumab has 10-15% pneumonitis rate. Classic presentation with new GGO and negative infection workup.\",\"temporal_relationship\":\"During consolidation durvalumab\",\"alternative_causes\":[],\"supporting_factors\":[\"Post-CRT durvalumab (high risk)\",\"New bilateral GGO on CT\",\"Negative infection workup\",\"Classic symptom pattern\"],\"against_factors\":[\"O2 sat 94% - borderline\"]},\"overall_severity\":\"Grade 2 - Moderate\",\"severity_reasoning\":\"CTCAE Grade 2 Pneumonitis: Symptomatic, medical intervention indicated, limiting instrumental ADL.\",\"urgency\":\"soon\",\"urgency_reasoning\":\"Grade 2 pneumonitis requires oncology review to initiate steroids\",\"recommended_actions\":[{\"action\":\"Hold durvalumab\",\"priority\":1,\"rationale\":\"Grade 2 pneumonitis requires treatment hold\"},{\"action\":\"Start prednisone 1-2mg/kg daily\",\"priority\":1,\"rationale\":\"Standard treatment for Grade 2 pneumonitis\"},{\"action\":\"Bronchoscopy with BAL if diagnostic uncertainty\",\"priority\":2,\"rationale\":\"Can confirm diagnosis and rule out infection\"},{\"action\":\"Follow-up CT in 3-4 weeks\",\"priority\":2,\"rationale\":\"Assess response to steroids\"}],\"key_evidence\":[\"New bilateral GGO on CT\",\"Dry cough and dyspnea\",\"O2 sat 94%\",\"Low procalcitonin\",\"Negative cultures\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: LUNG-002\nAge: 71\nCancer Type: Non-small cell lung cancer\n\nMEDICATIONS:\nPembrolizumab 200mg IV q3weeks, Oxygen 4L NC, Azithromycin 500mg daily (started empirically)\n\nLABORATORY VALUES:\nWBC: 11.5 x10^9/L, LDH: 450 U/L (H), CRP: 12.5 mg/dL (H), PaO2: 58 mmHg on 4L NC, Procalcitonin: 0.2 ng/mL\n\nSYMPTOMS:\nSevere dyspnea at rest, Persistent dry cough, Hypoxia requiring supplemental O2, Tachypnea - RR 28, No fever\n\nCLINICAL NOTES:\nPatient on pembrolizumab for stage IV NSCLC. Progressive dyspnea over 1 week, now requiring 4L O2. CT shows extensive bilateral GGO and consolidation. BAL cultures negative. Considering ICU transfer.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on pembrolizumab (PD-1 inhibitor)\",\"step2_organ_findings\":\"Pulmonary: Severe hypoxemia (PaO2 58), requiring O2, extensive GGO\",\"step3_severity_rationale\":\"CTCAE Grade 3 pneumonitis: Severe symptoms, oxygen indicated\",\"step4_causality_rationale\":\"Classic severe pneumonitis with negative BAL\",\"step5_urgency_rationale\":\"Grade 3 with significant hypoxemia = EMERGENCY\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"pembrolizumab\"],\"drug_classes\":[\"PD-1\"],\"combination_therapy\":false,\"context_notes\":\"Active pembrolizumab therapy\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Pulmonary\",\"detected\":true,\"findings\":[\"Severe dyspnea at rest\",\"Hypoxia requiring 4L O2\",\"Tachypnea RR 28\",\"Extensive bilateral GGO\"],\"evidence\":[\"PaO2 58 mmHg\",\"Negative BAL cultures\",\"Low procalcitonin\"],\"severity\":\"Grade 3\"}],\"causality\":{\"likelihood\":\"Highly likely\",\"reasoning\":\"Severe hypoxemia on pembrolizumab with extensive bilateral infiltrates and negative infection workup.\",\"temporal_relationship\":\"During active immunotherapy\",\"alternative_causes\":[],\"supporting_factors\":[\"On checkpoint inhibitor\",\"Severe hypoxemia requiring O2\",\"Extensive bilateral infiltrates\",\"Negative BAL cultures\",\"Low procalcitonin\"],\"against_factors\":[]},\"overall_severity\":\"Grade 3 - Severe\",\"severity_reasoning\":\"CTCAE Grade 3 Pneumonitis: Severe symptoms, oxygen indicated, limiting self-care ADL.\",\"urgency\":\"emergency\",\"urgency_reasoning\":\"Grade 3 pneumonitis with significant hypoxemia requires emergency ICU evaluation\",\"recommended_actions\":[{\"action\":\"Permanently discontinue pembrolizumab\",\"priority\":1,\"rationale\":\"Grade 3 pneumonitis requires permanent discontinuation\"},{\"action\":\"IV methylprednisolone 2-4mg/kg/day\",\"priority\":1,\"rationale\":\"High-dose IV steroids for severe pneumonitis\"},{\"action\":\"ICU admission for monitoring\",\"priority\":1,\"rationale\":\"Severe hypoxemia requires close monitoring\"},{\"action\":\"Pulmonology consultation\",\"priority\":1,\"rationale\":\"Specialist input for severe pneumonitis\"},{\"action\":\"Consider infliximab if no response in 48h\",\"priority\":2,\"rationale\":\"Steroid-refractory pneumonitis may need additional immunosuppression\"}],\"key_evidence\":[\"PaO2 58 on 4L O2\",\"Extensive bilateral GGO\",\"Tachypnea RR 28\",\"Negative BAL cultures\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: ENDO-001\nAge: 55\nCancer Type: Renal cell carcinoma\n\nMEDICATIONS:\nNivolumab 240mg IV q2weeks, Amlodipine 5mg daily\n\nLABORATORY VALUES:\nTSH: 28.5 mIU/L (H) - baseline 2.1, Free T4: 0.4 ng/dL (L), Free T3: 1.8 pg/mL (L), Anti-TPO: positive\n\nSYMPTOMS:\nFatigue - progressive over 4 weeks, Weight gain - 8 lbs in 1 month, Cold intolerance, Constipation, Dry skin\n\nCLINICAL NOTES:\nPatient on nivolumab for metastatic RCC. Progressive fatigue and weight gain over past month. TSH markedly elevated with low free T4. Classic hypothyroid symptoms present.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on nivolumab (PD-1 inhibitor)\",\"step2_organ_findings\":\"Endocrine: TSH 28.5 (very elevated), low T4, classic hypothyroid symptoms\",\"step3_severity_rationale\":\"CTCAE Grade 2 hypothyroidism: Symptomatic, thyroid replacement indicated\",\"step4_causality_rationale\":\"On PD-1 inhibitor with anti-TPO positive - immune thyroiditis\",\"step5_urgency_rationale\":\"Grade 2 = 'soon', but ICI can CONTINUE with replacement\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"nivolumab\"],\"drug_classes\":[\"PD-1\"],\"combination_therapy\":false,\"context_notes\":\"Active nivolumab therapy\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Endocrine\",\"detected\":true,\"findings\":[\"TSH 28.5 mIU/L (elevated)\",\"Free T4 0.4 ng/dL (low)\",\"Anti-TPO positive\"],\"evidence\":[\"Classic hypothyroid symptoms\",\"Progressive fatigue\",\"Weight gain\"],\"severity\":\"Grade 2\"}],\"causality\":{\"likelihood\":\"Highly likely\",\"reasoning\":\"PD-1 inhibitor with markedly elevated TSH, low T4, positive anti-TPO, and classic symptoms = immune thyroiditis.\",\"temporal_relationship\":\"During active immunotherapy\",\"alternative_causes\":[],\"supporting_factors\":[\"On checkpoint inhibitor\",\"TSH 28.5\",\"Low free T4\",\"Anti-TPO positive\",\"Classic symptoms\"],\"against_factors\":[]},\"overall_severity\":\"Grade 2 - Moderate\",\"severity_reasoning\":\"CTCAE Grade 2 Hypothyroidism: Symptomatic, thyroid replacement indicated.\",\"urgency\":\"soon\",\"urgency_reasoning\":\"Hypothyroidism requires oncology review but is not urgent. ICI can typically CONTINUE with thyroid replacement.\",\"recommended_actions\":[{\"action\":\"Start levothyroxine replacement\",\"priority\":1,\"rationale\":\"Overt hypothyroidism requires hormone replacement\"},{\"action\":\"Can continue nivolumab\",\"priority\":2,\"rationale\":\"Unlike other irAEs, hypothyroidism does not require ICI discontinuation\"},{\"action\":\"Recheck TSH in 6-8 weeks\",\"priority\":2,\"rationale\":\"Monitor response to replacement therapy\"},{\"action\":\"Endocrinology referral if needed\",\"priority\":3,\"rationale\":\"For dose adjustment and long-term management\"}],\"key_evidence\":[\"TSH 28.5 mIU/L\",\"Free T4 0.4 ng/dL\",\"Anti-TPO positive\",\"Classic hypothyroid symptoms\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: ENDO-002\nAge: 62\nCancer Type: Melanoma\n\nMEDICATIONS:\nIpilimumab 3mg/kg IV q3weeks (4th dose), Hydrochlorothiazide 25mg daily\n\nLABORATORY VALUES:\nACTH: 5 pg/mL (L), Cortisol (AM): 2.1 ug/dL (L), TSH: 0.5 mIU/L (L), Free T4: 0.6 ng/dL (L), LH: 1.2 mIU/mL (L), FSH: 2.0 mIU/mL (L), Testosterone: 85 ng/dL (L), Prolactin: 45 ng/mL (H)\n\nSYMPTOMS:\nSevere headache - frontal, Profound fatigue, Nausea, Visual disturbance - none, Dizziness on standing\n\nCLINICAL NOTES:\nPatient after 4th dose of ipilimumab for melanoma. New severe headache and fatigue over past week. Labs show panhypopituitarism pattern. MRI pituitary shows enlarged gland with heterogeneous enhancement.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on ipilimumab (CTLA-4 inhibitor) - 5-10% hypophysitis rate\",\"step2_organ_findings\":\"Endocrine: Panhypopituitarism pattern with low cortisol - LIFE THREATENING\",\"step3_severity_rationale\":\"CTCAE Grade 3: Adrenal insufficiency is severe/life-threatening\",\"step4_causality_rationale\":\"Ipilimumab + panhypopituitarism + enlarged pituitary on MRI = classic hypophysitis\",\"step5_urgency_rationale\":\"Grade 3 with adrenal insufficiency = URGENT (life-threatening)\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"ipilimumab\"],\"drug_classes\":[\"CTLA-4\"],\"combination_therapy\":false,\"context_notes\":\"After 4th dose - highest hypophysitis risk window\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Endocrine\",\"detected\":true,\"findings\":[\"Cortisol 2.1 (critically low)\",\"ACTH 5 (low)\",\"Panhypopituitarism pattern\",\"Enlarged pituitary on MRI\"],\"evidence\":[\"Severe headache\",\"Dizziness on standing\",\"Ipilimumab exposure\"],\"severity\":\"Grade 3\"}],\"causality\":{\"likelihood\":\"Highly likely\",\"reasoning\":\"Ipilimumab (5-10% hypophysitis rate) with panhypopituitarism labs and MRI showing enlarged pituitary = classic immune hypophysitis.\",\"temporal_relationship\":\"After 4th dose of ipilimumab\",\"alternative_causes\":[],\"supporting_factors\":[\"Ipilimumab (highest hypophysitis risk)\",\"Panhypopituitarism labs\",\"MRI showing enlarged pituitary\",\"Classic headache presentation\"],\"against_factors\":[]},\"overall_severity\":\"Grade 3 - Severe\",\"severity_reasoning\":\"CTCAE Grade 3: Severe symptoms with adrenal insufficiency (cortisol 2.1). Low cortisol is life-threatening.\",\"urgency\":\"urgent\",\"urgency_reasoning\":\"Adrenal insufficiency is life-threatening. Needs immediate stress-dose hydrocortisone.\",\"recommended_actions\":[{\"action\":\"IMMEDIATE stress-dose hydrocortisone 100mg IV\",\"priority\":1,\"rationale\":\"Adrenal insufficiency is life-threatening\"},{\"action\":\"Hold ipilimumab\",\"priority\":1,\"rationale\":\"Grade 3 hypophysitis requires treatment hold\"},{\"action\":\"Endocrinology consultation urgent\",\"priority\":1,\"rationale\":\"Specialist input for hormone replacement\"},{\"action\":\"Start thyroid replacement AFTER cortisol\",\"priority\":2,\"rationale\":\"CRITICAL: Starting levothyroxine before cortisol can precipitate adrenal crisis\"}],\"key_evidence\":[\"Cortisol 2.1 ug/dL (critically low)\",\"ACTH 5 pg/mL (low)\",\"Panhypopituitarism pattern\",\"MRI shows enlarged pituitary\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: CARD-001\nAge: 61\nCancer Type: Melanoma\n\nMEDICATIONS:\nIpilimumab 3mg/kg + Nivolumab 1mg/kg IV q3weeks, Metoprolol 25mg BID, Lisinopril 10mg daily\n\nLABORATORY VALUES:\nTroponin I: 2.8 ng/mL (H), CK-MB: 45 ng/mL (H), BNP: 850 pg/mL (H), CRP: 8.5 mg/dL (H), CK: 1200 U/L (H)\n\nSYMPTOMS:\nChest pain - substernal, worse with exertion, Dyspnea - progressive, Palpitations, Fatigue - severe, Orthopnea\n\nCLINICAL NOTES:\nPatient on combination ipilimumab/nivolumab for melanoma. Chest pain and dyspnea started 5 days ago. ECG shows diffuse ST changes and low voltage. Echo shows EF 35% (baseline 60%). Troponin elevated. Urgent cardiology consult for suspected ICI myocarditis.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on combination ICI (ipilimumab + nivolumab) - HIGHEST myocarditis risk\",\"step2_organ_findings\":\"Cardiac: Troponin 2.8, EF drop 60%→35%, ECG changes, BNP elevated\",\"step3_severity_rationale\":\"CTCAE Grade 4: Life-threatening cardiac dysfunction\",\"step4_causality_rationale\":\"Combination ICI + classic myocarditis pattern + elevated CK (possible myositis)\",\"step5_urgency_rationale\":\"Cardiac = ALWAYS EMERGENCY (25-50% mortality)\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"ipilimumab\",\"nivolumab\"],\"drug_classes\":[\"CTLA-4\",\"PD-1\"],\"combination_therapy\":true,\"context_notes\":\"Combination ICI - highest myocarditis risk\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Cardiac\",\"detected\":true,\"findings\":[\"Troponin I 2.8 ng/mL\",\"EF drop from 60% to 35%\",\"ECG changes\",\"BNP 850\"],\"evidence\":[\"Elevated CK (possible concurrent myositis)\",\"Classic symptoms\",\"Combination ICI\"],\"severity\":\"Grade 4\"}],\"causality\":{\"likelihood\":\"Highly likely\",\"reasoning\":\"Combination ICI with elevated troponin, significant EF reduction, ECG changes, and elevated CK (possible myositis overlap).\",\"temporal_relationship\":\"During combination immunotherapy\",\"alternative_causes\":[],\"supporting_factors\":[\"Combination ICI (highest myocarditis risk)\",\"Troponin 2.8 ng/mL\",\"EF drop from 60% to 35%\",\"ECG changes\",\"Elevated CK\"],\"against_factors\":[]},\"overall_severity\":\"Grade 4 - Life-threatening\",\"severity_reasoning\":\"CTCAE Grade 4: Life-threatening cardiac dysfunction. Troponin elevation with significant EF reduction indicates severe myocardial injury.\",\"urgency\":\"emergency\",\"urgency_reasoning\":\"ICI myocarditis has 25-50% mortality rate. This is a MEDICAL EMERGENCY.\",\"recommended_actions\":[{\"action\":\"IMMEDIATE permanent discontinuation of all ICIs\",\"priority\":1,\"rationale\":\"Myocarditis requires permanent discontinuation\"},{\"action\":\"ICU admission with continuous telemetry\",\"priority\":1,\"rationale\":\"High risk of arrhythmia and hemodynamic collapse\"},{\"action\":\"IV methylprednisolone 1g daily\",\"priority\":1,\"rationale\":\"High-dose steroids for life-threatening myocarditis\"},{\"action\":\"Emergent cardiology consultation\",\"priority\":1,\"rationale\":\"Specialist input critical\"},{\"action\":\"Have IVIG and plasmapheresis available\",\"priority\":2,\"rationale\":\"May need escalation if steroid-refractory\"}],\"key_evidence\":[\"Troponin I 2.8 ng/mL\",\"EF 35% (baseline 60%)\",\"BNP 850\",\"ECG changes\",\"Combination ICI\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: NEURO-001\nAge: 68\nCancer Type: Small cell lung cancer\n\nMEDICATIONS:\nNivolumab 240mg IV q2weeks, Pyridostigmine 60mg TID (started 2 days ago)\n\nLABORATORY VALUES:\nCK: 180 U/L, Acetylcholine receptor antibodies: positive, Anti-striated muscle antibodies: positive, Troponin: 0.08 ng/mL (slightly elevated)\n\nSYMPTOMS:\nBilateral ptosis, Diplopia, Dysphagia - mild, Proximal muscle weakness, Fatigue worse with activity\n\nCLINICAL NOTES:\nPatient on nivolumab for extensive stage SCLC. Developed ptosis and diplopia over 1 week. Fatigable weakness on exam. Ice pack test positive. AChR antibodies positive. Concerned for irAE MG. Monitor for respiratory involvement.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on nivolumab (PD-1 inhibitor)\",\"step2_organ_findings\":\"Neurologic: Ptosis, diplopia, dysphagia, AChR positive, anti-striated muscle positive\",\"step3_severity_rationale\":\"CTCAE Grade 2 but HIGH RISK - MG can progress to crisis, myocarditis risk\",\"step4_causality_rationale\":\"Classic MG presentation on ICI with positive antibodies\",\"step5_urgency_rationale\":\"Neurologic = ALWAYS URGENT regardless of grade\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"nivolumab\"],\"drug_classes\":[\"PD-1\"],\"combination_therapy\":false,\"context_notes\":\"Active nivolumab therapy\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Neurologic\",\"detected\":true,\"findings\":[\"Bilateral ptosis\",\"Diplopia\",\"Dysphagia\",\"Fatigable weakness\"],\"evidence\":[\"AChR antibodies positive\",\"Anti-striated muscle antibodies positive\",\"Slightly elevated troponin\"],\"severity\":\"Grade 2\"}],\"causality\":{\"likelihood\":\"Highly likely\",\"reasoning\":\"PD-1 inhibitor with positive AChR antibodies, positive anti-striated muscle antibodies, and classic MG symptoms. Anti-striated muscle antibodies indicate 20-40% risk of concurrent myocarditis.\",\"temporal_relationship\":\"During active immunotherapy\",\"alternative_causes\":[],\"supporting_factors\":[\"On checkpoint inhibitor\",\"AChR antibodies positive\",\"Anti-striated muscle antibodies positive\",\"Classic MG symptoms\",\"Slightly elevated troponin\"],\"against_factors\":[]},\"overall_severity\":\"Grade 2 - Moderate\",\"severity_reasoning\":\"CTCAE Grade 2 but URGENT due to MG crisis risk and concurrent myocarditis concern.\",\"urgency\":\"urgent\",\"urgency_reasoning\":\"ICI-related MG can progress rapidly to respiratory failure. Anti-striated muscle antibodies + elevated troponin suggest possible concurrent myocarditis.\",\"recommended_actions\":[{\"action\":\"Permanently discontinue nivolumab\",\"priority\":1,\"rationale\":\"ICI-related MG requires permanent discontinuation\"},{\"action\":\"Neurology consultation urgent\",\"priority\":1,\"rationale\":\"Specialist input for MG management\"},{\"action\":\"Serial FVC monitoring q4-6h\",\"priority\":1,\"rationale\":\"Monitor for MG crisis and respiratory failure\"},{\"action\":\"Check troponin daily and get cardiac workup\",\"priority\":1,\"rationale\":\"Anti-striated muscle antibodies indicate myocarditis risk\"},{\"action\":\"Start prednisone 1mg/kg\",\"priority\":1,\"rationale\":\"Steroids for immune-related MG\"}],\"key_evidence\":[\"AChR antibodies positive\",\"Anti-striated muscle antibodies positive\",\"Troponin 0.08\",\"Ptosis and diplopia\",\"Dysphagia\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: NEURO-002\nAge: 54\nCancer Type: Non-small cell lung cancer\n\nMEDICATIONS:\nPembrolizumab 200mg IV q3weeks, Levetiracetam 1000mg BID (started after seizure), Methylprednisolone 1g IV daily\n\nLABORATORY VALUES:\nCSF: WBC 45 (lymphocyte predominant), CSF protein: 85 mg/dL (H), CSF glucose: 55 mg/dL (normal), MRI brain: bilateral medial temporal lobe hyperintensity\n\nSYMPTOMS:\nConfusion - acute onset, Memory impairment, Seizure - witnessed generalized tonic-clonic, Headache, Personality change\n\nCLINICAL NOTES:\nPatient on pembrolizumab for NSCLC. Acute confusion and witnessed seizure 3 days ago. MRI shows bilateral medial temporal lobe T2 hyperintensity. LP shows lymphocytic pleocytosis. Autoimmune encephalitis workup sent. Started high-dose steroids.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on pembrolizumab (PD-1 inhibitor)\",\"step2_organ_findings\":\"Neurologic: Limbic encephalitis pattern - confusion, seizure, memory impairment, MRI findings, inflammatory CSF\",\"step3_severity_rationale\":\"CTCAE Grade 3-4: Seizure and significant encephalopathy\",\"step4_causality_rationale\":\"Classic limbic encephalitis pattern with inflammatory CSF\",\"step5_urgency_rationale\":\"Neurologic with seizure = EMERGENCY\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"pembrolizumab\"],\"drug_classes\":[\"PD-1\"],\"combination_therapy\":false,\"context_notes\":\"Active pembrolizumab therapy\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Neurologic\",\"detected\":true,\"findings\":[\"Acute confusion\",\"Seizure\",\"Memory impairment\",\"Bilateral medial temporal hyperintensity\"],\"evidence\":[\"CSF WBC 45 (lymphocytic)\",\"CSF protein 85\",\"Normal CSF glucose\"],\"severity\":\"Grade 3\"}],\"causality\":{\"likelihood\":\"Highly likely\",\"reasoning\":\"Pembrolizumab with acute encephalopathy, seizure, bilateral medial temporal MRI findings (limbic encephalitis pattern), and inflammatory CSF.\",\"temporal_relationship\":\"During active immunotherapy\",\"alternative_causes\":[],\"supporting_factors\":[\"On checkpoint inhibitor\",\"Limbic encephalitis pattern on MRI\",\"Inflammatory CSF\",\"Seizure\",\"Acute confusion\"],\"against_factors\":[\"Normal CSF glucose argues against infectious meningitis\"]},\"overall_severity\":\"Grade 3 - Severe\",\"severity_reasoning\":\"CTCAE Grade 3-4: Seizure and significant encephalopathy indicate severe neurologic toxicity.\",\"urgency\":\"emergency\",\"urgency_reasoning\":\"Immune-related encephalitis with seizure is a neurologic emergency requiring ICU admission.\",\"recommended_actions\":[{\"action\":\"Permanently discontinue pembrolizumab\",\"priority\":1,\"rationale\":\"Severe neurologic toxicity requires permanent discontinuation\"},{\"action\":\"Continue IV methylprednisolone 1g daily x 3-5 days\",\"priority\":1,\"rationale\":\"High-dose steroids for encephalitis\"},{\"action\":\"Neurology consultation urgent\",\"priority\":1,\"rationale\":\"Specialist input critical\"},{\"action\":\"EEG monitoring\",\"priority\":1,\"rationale\":\"Monitor for subclinical seizures\"},{\"action\":\"ICU admission for neuro monitoring\",\"priority\":1,\"rationale\":\"Encephalitis with seizure requires close monitoring\"},{\"action\":\"Consider IVIG if steroid-refractory\",\"priority\":2,\"rationale\":\"May need additional immunosuppression\"}],\"key_evidence\":[\"Bilateral medial temporal hyperintensity\",\"CSF WBC 45 (lymphocytic)\",\"CSF protein 85\",\"Witnessed seizure\",\"Acute confusion\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: NEG-001\nAge: 45\nCancer Type: Melanoma\n\nMEDICATIONS:\nPembrolizumab 200mg IV q3weeks, Metformin 1000mg BID, Lisinopril 10mg daily\n\nLABORATORY VALUES:\nWBC: 7.5 x10^9/L, Hemoglobin: 13.5 g/dL, AST: 25 U/L, ALT: 28 U/L, TSH: 2.1 mIU/L, Creatinine: 0.9 mg/dL\n\nSYMPTOMS:\nMild fatigue - ongoing, No GI symptoms, No respiratory symptoms\n\nCLINICAL NOTES:\nRoutine follow-up visit. Patient on cycle 6 of pembrolizumab for stage III melanoma with good response. Labs unremarkable. Mild baseline fatigue unchanged from prior visits. No new concerns.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on pembrolizumab (PD-1 inhibitor) cycle 6\",\"step2_organ_findings\":\"All systems within normal limits. Labs unremarkable. Fatigue is baseline/unchanged.\",\"step3_severity_rationale\":\"No abnormalities detected - no grading applicable\",\"step4_causality_rationale\":\"No irAE signals present\",\"step5_urgency_rationale\":\"Routine monitoring appropriate\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"pembrolizumab\"],\"drug_classes\":[\"PD-1\"],\"combination_therapy\":false,\"context_notes\":\"Cycle 6, good treatment response\"},\"irae_detected\":false,\"affected_systems\":[{\"system\":\"Gastrointestinal\",\"detected\":false,\"findings\":[],\"evidence\":[],\"severity\":\"Unknown\"},{\"system\":\"Hepatic\",\"detected\":false,\"findings\":[],\"evidence\":[\"Normal AST/ALT\"],\"severity\":\"Unknown\"},{\"system\":\"Endocrine\",\"detected\":false,\"findings\":[],\"evidence\":[\"Normal TSH\"],\"severity\":\"Unknown\"}],\"causality\":{\"likelihood\":\"Unlikely\",\"reasoning\":\"No clinical or laboratory evidence of irAE. All values within normal limits. Fatigue is baseline and unchanged.\",\"temporal_relationship\":\"During active immunotherapy\",\"alternative_causes\":[\"Baseline fatigue\",\"Cancer-related fatigue\"],\"supporting_factors\":[],\"against_factors\":[\"Normal labs\",\"No new symptoms\",\"Fatigue unchanged from baseline\"]},\"overall_severity\":\"Unknown\",\"severity_reasoning\":\"No irAE detected - no severity grading applicable.\",\"urgency\":\"routine\",\"urgency_reasoning\":\"No irAE signals. Continue routine monitoring at scheduled visits.\",\"recommended_actions\":[{\"action\":\"Continue pembrolizumab as scheduled\",\"priority\":1,\"rationale\":\"No evidence of toxicity\"},{\"action\":\"Routine lab monitoring\",\"priority\":2,\"rationale\":\"Standard of care surveillance\"},{\"action\":\"Counsel on irAE warning signs\",\"priority\":3,\"rationale\":\"Patient education for early detection\"}],\"key_evidence\":[\"Normal AST/ALT\",\"Normal TSH\",\"Normal CBC\",\"Unchanged baseline fatigue\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: NEG-002\nAge: 72\nCancer Type: NSCLC\n\nMEDICATIONS:\nNivolumab 240mg IV q2weeks, Levofloxacin 750mg daily (started 3 days ago), Ibuprofen 400mg PRN\n\nLABORATORY VALUES:\nWBC: 14.2 x10^9/L (H), CRP: 6.5 mg/dL (H), Procalcitonin: 1.2 ng/mL (H), Creatinine: 1.1 mg/dL\n\nSYMPTOMS:\nProductive cough with yellow sputum, Fever - 38.5°C, Chills, No diarrhea\n\nCLINICAL NOTES:\nPatient on nivolumab for NSCLC. Presents with 4-day history of productive cough, fever, and chills. CXR shows right lower lobe consolidation consistent with community-acquired pneumonia. Started on levofloxacin. No GI symptoms.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on nivolumab (PD-1 inhibitor)\",\"step2_organ_findings\":\"Pulmonary findings BUT with high procalcitonin, productive cough, focal consolidation = BACTERIAL PNEUMONIA, not pneumonitis\",\"step3_severity_rationale\":\"This is infectious, not immune-related\",\"step4_causality_rationale\":\"High procalcitonin (1.2) strongly suggests bacterial infection, not irAE\",\"step5_urgency_rationale\":\"Infection needs treatment, but not irAE protocol\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"nivolumab\"],\"drug_classes\":[\"PD-1\"],\"combination_therapy\":false,\"context_notes\":\"Active nivolumab therapy\"},\"irae_detected\":false,\"affected_systems\":[{\"system\":\"Pulmonary\",\"detected\":false,\"findings\":[\"RLL consolidation on CXR\"],\"evidence\":[\"High procalcitonin 1.2\",\"Productive cough with purulent sputum\",\"Focal consolidation\",\"Fever with chills\"],\"severity\":\"Unknown\"}],\"causality\":{\"likelihood\":\"Unlikely\",\"reasoning\":\"Clinical presentation (productive cough, purulent sputum, focal consolidation, high procalcitonin) is consistent with bacterial CAP, NOT immune-related pneumonitis.\",\"temporal_relationship\":\"During active immunotherapy\",\"alternative_causes\":[\"Community-acquired bacterial pneumonia - most likely\"],\"supporting_factors\":[],\"against_factors\":[\"High procalcitonin (1.2 ng/mL) strongly suggests bacterial infection\",\"Productive cough with purulent sputum (pneumonitis typically dry)\",\"Focal consolidation (pneumonitis typically bilateral GGO)\",\"Fever with chills (less common in pneumonitis)\"]},\"overall_severity\":\"Unknown\",\"severity_reasoning\":\"Not an irAE - this is likely bacterial pneumonia requiring antibiotic treatment.\",\"urgency\":\"soon\",\"urgency_reasoning\":\"Patient needs follow-up for bacterial pneumonia, but this is NOT an irAE requiring oncology intervention.\",\"recommended_actions\":[{\"action\":\"Continue antibiotic therapy for bacterial pneumonia\",\"priority\":1,\"rationale\":\"Treat underlying infection\"},{\"action\":\"Can continue nivolumab after infection resolves\",\"priority\":2,\"rationale\":\"Bacterial infection is not a contraindication to ICI\"},{\"action\":\"Follow-up CXR in 4-6 weeks\",\"priority\":2,\"rationale\":\"Ensure pneumonia resolution\"},{\"action\":\"If no improvement on antibiotics, reassess for pneumonitis\",\"priority\":3,\"rationale\":\"May need broader differential if not responding\"}],\"key_evidence\":[\"Procalcitonin 1.2 ng/mL (elevated - suggests bacterial)\",\"Productive cough with yellow sputum\",\"Focal RLL consolidation\",\"Fever 38.5°C with chills\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: SKIN-001\nAge: 58\nCancer Type: Melanoma\n\nMEDICATIONS:\nPembrolizumab 200mg IV q3weeks, Cetirizine 10mg daily, Hydrocortisone cream 1% PRN\n\nLABORATORY VALUES:\nWBC: 8.2 x10^9/L, Eosinophils: 0.8 x10^9/L (H), CRP: 1.2 mg/dL (mildly elevated)\n\nSYMPTOMS:\nMaculopapular rash - trunk and extremities, Pruritus - moderate, No mucosal involvement, No blistering\n\nCLINICAL NOTES:\nPatient on cycle 3 of pembrolizumab. Developed diffuse maculopapular rash over trunk and extremities 10 days ago. Covers approximately 20% BSA. Moderate itching. No blistering, no mucosal involvement. Responding to topical steroids and antihistamines.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on pembrolizumab (PD-1 inhibitor) cycle 3\",\"step2_organ_findings\":\"Skin: Maculopapular rash 20% BSA, pruritic, no severe features\",\"step3_severity_rationale\":\"CTCAE Grade 2 rash: 10-30% BSA, symptomatic, limits ADL\",\"step4_causality_rationale\":\"Classic timing and presentation for ICI-related dermatitis\",\"step5_urgency_rationale\":\"Grade 2 = 'soon', responding to topical treatment\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"pembrolizumab\"],\"drug_classes\":[\"PD-1\"],\"combination_therapy\":false,\"context_notes\":\"Cycle 3 of pembrolizumab\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Skin\",\"detected\":true,\"findings\":[\"Maculopapular rash\",\"20% BSA involvement\",\"Moderate pruritus\"],\"evidence\":[\"Elevated eosinophils\",\"Responding to topical treatment\"],\"severity\":\"Grade 2\"}],\"causality\":{\"likelihood\":\"Possible\",\"reasoning\":\"PD-1 inhibitor with typical maculopapular rash pattern at expected timing. Eosinophilia supports immune etiology.\",\"temporal_relationship\":\"Onset during cycle 3\",\"alternative_causes\":[\"Drug reaction to other medication\"],\"supporting_factors\":[\"On checkpoint inhibitor\",\"Typical rash pattern\",\"Elevated eosinophils\",\"Expected timing\"],\"against_factors\":[\"Could be coincidental drug reaction\"]},\"overall_severity\":\"Grade 2 - Moderate\",\"severity_reasoning\":\"CTCAE Grade 2 Rash: 10-30% BSA, symptomatic, limiting instrumental ADL due to pruritus.\",\"urgency\":\"soon\",\"urgency_reasoning\":\"Grade 2 dermatitis usually manageable but needs oncology input on ICI continuation.\",\"recommended_actions\":[{\"action\":\"Continue topical corticosteroids\",\"priority\":1,\"rationale\":\"Grade 2 rash typically responds to topicals\"},{\"action\":\"May continue pembrolizumab with close monitoring\",\"priority\":2,\"rationale\":\"Grade 2 skin toxicity usually does not require ICI hold\"},{\"action\":\"Consider oral antihistamines for pruritus\",\"priority\":2,\"rationale\":\"Symptomatic relief\"},{\"action\":\"Dermatology referral if worsening\",\"priority\":3,\"rationale\":\"Specialist input if progressing\"}],\"key_evidence\":[\"Maculopapular rash 20% BSA\",\"Moderate pruritus\",\"Elevated eosinophils\",\"Responding to topical steroids\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: RENAL-001\nAge: 66\nCancer Type: Renal cell carcinoma\n\nMEDICATIONS:\nNivolumab 240mg IV q2weeks, Lisinopril 20mg daily (on hold), Furosemide 40mg daily\n\nLABORATORY VALUES:\nCreatinine: 3.2 mg/dL (H) - baseline 1.1, BUN: 45 mg/dL (H), Potassium: 5.8 mEq/L (H), Urinalysis: WBC casts, sterile pyuria, no bacteria\n\nSYMPTOMS:\nDecreased urine output, Mild edema, No flank pain, No dysuria\n\nCLINICAL NOTES:\nPatient on nivolumab for metastatic RCC. Creatinine rising over 2 weeks from baseline 1.1 to 3.2. ACE inhibitor held. Urinalysis shows WBC casts and sterile pyuria. Renal ultrasound normal. Concern for immune-related nephritis vs ATN.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on nivolumab (PD-1 inhibitor)\",\"step2_organ_findings\":\"Renal: Creatinine 3.2 (baseline 1.1), WBC casts, sterile pyuria - classic nephritis pattern\",\"step3_severity_rationale\":\"CTCAE Grade 3: Creatinine >3x baseline\",\"step4_causality_rationale\":\"WBC casts and sterile pyuria on ICI highly suggestive of immune nephritis\",\"step5_urgency_rationale\":\"Grade 3 renal = URGENT\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"nivolumab\"],\"drug_classes\":[\"PD-1\"],\"combination_therapy\":false,\"context_notes\":\"Active nivolumab therapy\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Renal\",\"detected\":true,\"findings\":[\"Creatinine 3.2 (baseline 1.1)\",\"WBC casts on urinalysis\",\"Sterile pyuria\",\"Decreased urine output\"],\"evidence\":[\"Normal renal ultrasound\",\"ACE inhibitor held\"],\"severity\":\"Grade 3\"}],\"causality\":{\"likelihood\":\"Highly likely\",\"reasoning\":\"PD-1 inhibitor with creatinine rise >3x baseline, WBC casts, and sterile pyuria = classic immune nephritis pattern.\",\"temporal_relationship\":\"Progressive rise over 2 weeks during ICI\",\"alternative_causes\":[\"ATN (less likely given WBC casts)\"],\"supporting_factors\":[\"On checkpoint inhibitor\",\"Creatinine >3x baseline\",\"WBC casts\",\"Sterile pyuria\",\"Normal ultrasound\"],\"against_factors\":[\"Could be ATN\"]},\"overall_severity\":\"Grade 3 - Severe\",\"severity_reasoning\":\"CTCAE Grade 3 AKI: Creatinine >3x baseline (1.1 → 3.2 = 2.9x, borderline Grade 2-3).\",\"urgency\":\"urgent\",\"urgency_reasoning\":\"Grade 3 nephritis with hyperkalemia requires same-day evaluation.\",\"recommended_actions\":[{\"action\":\"Hold nivolumab\",\"priority\":1,\"rationale\":\"Grade 3 nephritis requires treatment hold\"},{\"action\":\"Start prednisone 1mg/kg or IV methylprednisolone\",\"priority\":1,\"rationale\":\"Standard treatment for immune nephritis\"},{\"action\":\"Nephrology consultation\",\"priority\":1,\"rationale\":\"Specialist input, may need biopsy\"},{\"action\":\"Manage hyperkalemia\",\"priority\":1,\"rationale\":\"Potassium 5.8 needs treatment\"},{\"action\":\"Consider renal biopsy if not improving\",\"priority\":2,\"rationale\":\"Confirm diagnosis if steroid-refractory\"}],\"key_evidence\":[\"Creatinine 3.2 (baseline 1.1)\",\"WBC casts\",\"Sterile pyuria\",\"Hyperkalemia 5.8\"]}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: MULTI-001\nAge: 59\nCancer Type: Melanoma\n\nMEDICATIONS:\nIpilimumab 3mg/kg + Nivolumab 1mg/kg IV q3weeks\n\nLABORATORY VALUES:\nAST: 245 U/L (H), ALT: 312 U/L (H), TSH: 0.1 mIU/L (L), Free T4: 2.8 ng/dL (H), Lipase: 380 U/L (H), CRP: 9.2 mg/dL (H)\n\nSYMPTOMS:\nFatigue - severe, Nausea and vomiting, Abdominal pain - epigastric, Palpitations, Tremor, Heat intolerance\n\nCLINICAL NOTES:\nPatient on combination ipi/nivo for metastatic melanoma. Presenting with multi-system symptoms. Labs show hepatitis (AST/ALT ~6-8x ULN), hyperthyroidism (suppressed TSH, elevated T4), and elevated lipase. Concern for multi-organ irAE.\n\nProvide assessment in JSON format."}, {"role": "assistant", "content": "{\"analysis_reasoning\":{\"step1_immunotherapy\":\"Patient on combination ICI (ipilimumab + nivolumab) - HIGHEST RISK\",\"step2_organ_findings\":\"MULTI-SYSTEM: Hepatic (AST/ALT 6-8x ULN), Endocrine (hyperthyroidism), GI (elevated lipase)\",\"step3_severity_rationale\":\"Hepatic is Grade 3 (>5x ULN), use HIGHEST severity\",\"step4_causality_rationale\":\"Combination ICI with classic multi-organ pattern\",\"step5_urgency_rationale\":\"Multi-system + Grade 3 = URGENT\"},\"immunotherapy_context\":{\"on_immunotherapy\":true,\"agents\":[\"ipilimumab\",\"nivolumab\"],\"drug_classes\":[\"CTLA-4\",\"PD-1\"],\"combination_therapy\":true,\"context_notes\":\"Combination ICI - highest risk for multi-organ toxicity\"},\"irae_detected\":true,\"affected_systems\":[{\"system\":\"Hepatic\",\"detected\":true,\"findings\":[\"AST 245 U/L (~6x ULN)\",\"ALT 312 U/L (~8x ULN)\"],\"evidence\":[\"Nausea\",\"Abdominal discomfort\"],\"severity\":\"Grade 3\"},{\"system\":\"Endocrine\",\"detected\":true,\"findings\":[\"TSH 0.1 (suppressed)\",\"Free T4 2.8 (elevated)\"],\"evidence\":[\"Palpitations\",\"Tremor\",\"Heat intolerance\"],\"severity\":\"Grade 2\"},{\"system\":\"Gastrointestinal\",\"detected\":true,\"findings\":[\"Lipase 380 (elevated)\",\"Epigastric pain\"],\"evidence\":[\"Nausea and vomiting\"],\"severity\":\"Grade 2\"}],\"causality\":{\"likelihood\":\"Highly likely\",\"reasoning\":\"Combination ICI with simultaneous hepatitis, thyroiditis, and pancreatitis = classic multi-organ irAE pattern.\",\"temporal_relationship\":\"During combination immunotherapy\",\"alternative_causes\":[],\"supporting_factors\":[\"Combination ICI (highest risk)\",\"Multiple organ involvement\",\"Classic patterns in each system\",\"No alternative etiology\"],\"against_factors\":[]},\"overall_severity\":\"Grade 3 - Severe\",\"severity_reasoning\":\"Use highest severity among affected systems. Hepatic is Grade 3 (AST/ALT >5x ULN).\",\"urgency\":\"urgent\",\"urgency_reasoning\":\"Multi-organ irAE with Grade 3 hepatitis requires same-day evaluation.\",\"recommended_actions\":[{\"action\":\"Hold combination immunotherapy\",\"priority\":1,\"rationale\":\"Multi-organ Grade 3 toxicity requires treatment hold\"},{\"action\":\"Start prednisone 1-2mg/kg for hepatitis\",\"priority\":1,\"rationale\":\"Grade 3 hepatitis needs steroids\"},{\"action\":\"Beta-blocker for hyperthyroid symptoms\",\"priority\":1,\"rationale\":\"Symptomatic management of thyrotoxicosis\"},{\"action\":\"Monitor lipase and symptoms for pancreatitis\",\"priority\":2,\"rationale\":\"May need NPO if pancreatitis worsens\"},{\"action\":\"Endocrinology consultation\",\"priority\":2,\"rationale\":\"Multi-endocrine involvement\"}],\"key_evidence\":[\"AST 245, ALT 312 (>5x ULN)\",\"TSH 0.1, Free T4 2.8\",\"Lipase 380\",\"Combination ICI\",\"Multi-system symptoms\"]}"}]}
